In this video, Dr Sara Tolaney underscores the positive overall survival outcomes from the monarchE trial, reinforcing the impact of adjuvant abemaciclib plus endocrine therapy in high-risk, hormone receptor (HR)-positive/HER2-negative early breast cancer, while also noting the sustained 5-year benefits observed with ribociclib and nonsteroidal aromatase inhibitors in the NATALEE trial. Read More ›

Real-world data from Finland highlight the persistent risk of recurrence in hormone receptor (HR)-positive/HER2-negative early breast cancer (EBC) patients meeting NATALEE and monarchE criteria, underscoring the need for improved treatment strategies beyond standard care. Read More ›

The SERENA-6 trial evaluates patient-reported outcomes for camizestrant combined with cyclin-dependent kinase (CDK)4/6 inhibitors in hormone receptor (HR)-positive/HER2-negative advanced breast cancer patients with emergent ESR1 mutations during first-line endocrine therapy. Read More ›

This study highlights nursing care improvements for oral mucositis in TROP2 antibody−drug conjugate (ADC)-treated patients, prioritizing prevention, patient education, and seamless dental care integration. Read More ›

The ELEANOR study explores extended adjuvant neratinib in HER2-positive/hormone receptor (HR)-positive early breast cancer, providing critical insights from clinical routine across multiple countries. Read More ›

This phase 2 trial investigates the efficacy and safety of anlotinib combined with fulvestrant in patients with hormone receptor (HR)-positive/HER2-negative metastatic breast cancer, focusing on secondary hormone resistance. Read More ›

This indirect treatment comparison evaluates the efficacy and outcomes of imlunestrant plus abemaciclib versus fulvestrant plus abemaciclib in estrogen receptor (ER)-positive/HER2-negative advanced breast cancer, based on data from 3 phase 3 trials. Read More ›

The phase 2 TACTIVE-N trial evaluates the efficacy and safety of vepdegestrant, a proteolysis-targeting chimera estrogen receptor (ER) degrader, versus anastrozole in postmenopausal patients with ER-positive/HER2-negative localized breast cancer. Read More ›

The monarchE trial investigates the prognostic and predictive value of Ki-67 index pre- and post-neoadjuvant chemotherapy, focusing on changes following treatment in hormone receptor (HR)-positive/HER2-negative localized breast cancer patients. Read More ›

Subgroup analysis from the phase 3 CAPItello-291 study evaluates the efficacy of capivasertib combined with fulvestrant as first- and second-line endocrine-based therapy in patients with PIK3CA/AKT1/PTEN-altered hormone receptor (HR)-positive advanced breast cancer, focusing on treatment outcomes. Read More ›